Trials / Completed
CompletedNCT07272265
The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study
The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With Hepatic Arterial Infusion Chemotherapy of FOLFOX for HCC: a Retrospective Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 300 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter，retrospective study to explore the effectiveness and safety of Atezo/Bev plus hepatic artery infusion chemotherapy (HAIC) among adult patients with high-risk HCC in real-world clinical practice in China. Eligible patients diagnosed with high-risk HCC initiating the study treatment of interest between 28 October 2020 and 31 June 2025 will be included in this study. Secondary data from medical records of approximately 10 sites across China will be utilized.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab & Bevacizumab | Atezolizumab 1200mg \& Bevacizumab 15mg/kg Q3W |
| PROCEDURE | FOLFOX-HAIC | hepatic artery infusion chemotherapy of oxaliplatin, leucovorin, and fluorouracil |
Timeline
- Start date
- 2020-10-28
- Primary completion
- 2025-05-31
- Completion
- 2025-11-10
- First posted
- 2025-12-09
- Last updated
- 2025-12-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07272265. Inclusion in this directory is not an endorsement.